Industries > Pharma > Generic Drugs Market Forecast 2017-2027
Generic Drugs Market Forecast 2017-2027
Growth in Leading Regional and National Markets – US, EU5, Asia-Pacific, Emerging Markets
The generic drugs market is expected to grow at a CAGR of 8.8% in the first half of the forecast period and CAGR of 7.0% in the second half of the forecast period. The market is expected to grow at a CAGR of 7.9% from 2015 to 2027. The market is estimated at $254.6bn in 2016, $384.0bn in 2021, and $574.7bn in 2027.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 304-page report you will receive 89 tables and 87 figures– all unavailable elsewhere.
The 303-page report provides clear detailed insight into the generic drugs market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
Report Scope
• Generic Drugs Market forecasts from 2017-2027
• Generic Drugs National Market forecasts from 2017-2027, covering:
– United States
– Germany
– France
– United Kingdom
– Italy
– Spain
– Japan
– China
– India
– Brazil
– Russia
– South Korea
– Turkey
– Mexico
• Analysis of the key factors driving and restraining the growth of the generic drugs market from 2017-2027
• Assessment of selected leading companies that hold major market shares in the generic drugs market.
Visiongain’s study is intended for anyone requiring commercial analyses for the Generic Drugs Market. You find data, trends and predictions.
Buy our report today Generic Drugs Market Forecast 2017-2027: Growth in Leading Regional and National Markets – US, EU5, Asia-Pacific, Emerging Markets.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Global Generic Drugs: Market Overview
1.2 Global Generic Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is this Report for?
1.7 Methodology
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2. An Introduction to Generic Drugs
2.1 An Introduction to the Rise of Generic Drugs
2.2 What Are Generic Drugs?
2.2.1 Generic Active Ingredients
2.3 A Brief Overview of the Pharmaceutical Industry
2.3.1 Brief History of Generic Drugs
2.3.2 The Hatch-Waxman Act: The Rise of Generics
2.4 Demonstrating Bioequivalence: A Major Factor in Approving Generics
2.5 Types of Generics - Authorised, Branded and Unbranded
2.6 Complex Generics
2.7 Classification of Generic Drugs Markets
2.8 Is Generic Substitution Bad News for Big Pharma Business?
2.8.1 The 'Ever greening' of Pharmaceutical Products
2.9 Regulation of Generic Drugs
2.9.1 Regulation in the US
2.9.1.1 Obtaining FDA Approval: NDAs and ANDAs
2.9.1.2 The Hatch-Waxman Act Title I: Promotion of Generic Drugs
2.9.1.3 The Hatch-Waxman Act Title II: Incentives for the Branded Industry
2.9.1.4 How Has the Hatch-Waxman Act Impacted upon the US Pharmaceutical Market?
2.9.1.5 How the Timing of Market Entry Influences Product Success
2.9.2 Regulation in Europe
2.9.2.1 EU Marketing Approval Procedures
2.9.2.2 The 8+2+1 Rule: EU Data Exclusivity
2.9.2.3 Supplementary Protection Certificates
2.9.2.4 Variation in Drug Development Regulations between European Countries
2.9.2.5 The Move towards the Harmonisation of Standards
2.9.2.6 The Impact of Europe’s Unitary Patent System on Generic Drugs:
2.9.2.7 In or Out: Unitary Patent Strategy for European Generic Drug Manufacturing
2.9.3 Regulation in Japan
2.9.4 Regulation in China
2.10 Compulsory Licensing
2.11 Market Definition and Scope of This Report
2.11.1 Market Sizing and Revenue Reporting
2.11.2 Currency Exchange Rates in This Report
3. Generic Drugs Market, 2017-2027
3.1 The Global Generic Drugs Market: Market Overview
3.1.1 Segmenting the Global Generic Drugs Market
3.2 The Rise of the Global Generic Drugs Market in 2016
3.3 Changes in the Regional Distribution of the Generic Drugs Market 2015-2016
3.4 The Global Generic Drugs Market: Sales Forecast 2017-2027
3.5 Generic Drugs: Regional Market Forecast 2017-2027
3.5.1 Changes in Generic Drug Regional Market Shares 2017-2027
3.6 Leading National Markets for Generic Drugs: Market Forecast 2017-2027
3.7 National Markets that will Drive Generic Drugs Growth
3.8 Changes in Market Shares by National Market, 2017-2027
3.9 Drivers and Restraints for the Global Generic Drugs Market 2017-2027
4. US Generic Drugs Market, 2017-2027
4.1 Generic Drugs in the US: Market Overview
4.1.1 The Effects of Generics on Healthcare Spending in the US
4.1.2 The Hatch-Waxman Act and Its Ongoing Effects
4.1.3 Consolidation in the Drug Development and Supply Chain Driving US Generics
4.2 US Historical Generic Penetration Rates
4.3 Leading Companies Operating within the US Generic Drugs Market
4.3.1 The Increasing Acceptance of Generics amongst Consumers
4.3.2 Affordable Care Act: Expanding Medicare Coverage
4.4 The US Generic Drugs Market: Drivers and Restraints 2017-2027
4.5 The US Generic Drugs Market Forecast: 2017-2027
4.6 The US Generic Drugs Market – Strategic Analysis
4.6.1 Will Biosimilars Dictate the Future of the US Generics Market?
4.6.2 The Backlog of ANDA Applications
4.6.3 The Generic Drug User Fee Amendments (GDUFA)
4.6.4 Shortages of Generic Drugs Will Restrain the Market
4.6.5 The Anti-Competitive ‘Pay for Delay’ Effect
4.7 US Generic Drugs Market: A Range of Factors Contributing to Growth
5. Leading European Generic Drugs Market, 2017-2027
5.1 European Generic Drugs: Market Overview
5.1.1 The EU5
5.1.2 Why Growth in Some Markets is Being Hindered?
5.1.3 Predominant Pricing Systems and Generic Penetration in European Markets
5.1.3.1 Lower Patient Co-Payments Drive for Generics
5.1.3.2 The Effects of Tendering for Generic Medicines
5.1.4 Will Europe Move towards Free-Pricing Systems?
5.1.5 Challenges in the European Regulatory Environment
5.1.6 Ending Anti-Competitive ‘Pay for Delay’ Tactics in Europe
5.1.7 FDA and EMA Joint Data Sharing and Inspections
5.2 EU5 Generic Drugs Market Forecast: 2017-2027
5.3 EU5 Market Share Breakdown 2017-2027
5.4 Germany: New Reforms to Medicinal Pricing May Impact Market Entry
5.4.1 German Generic Drugs Market: Generic Penetration by Volume, 2001-2016
5.4.2 German Generic Drugs Market: Generic Penetration by Value, 2001-2016
5.5 UK Generic Drugs Market: A Mature Market with Growth Potential
5.5.1 UK Generic Drugs Market: Sales Forecast 2017-2027
5.5.2 Cost Pressures and Demand-Side Policies Drive UK Generic Penetration
5.5.3 UK Generic Drugs Market: Generic Penetration by Volume, 2001-2016
5.5.4 UK Generic Drugs Market: Generic Penetration by Value, 2001-2016
5.5.5 Pharmacists as Enforcers of Generic Substitution
5.5.6 Pay Time for ‘Pay-For-Delay’
5.5.7 GSK: Widening the Gate to Accessible Medicines
5.6 French Generic Drugs Market: Healthcare Reforms Impacting on Market Growth
5.6.1 French Generic Drugs Market: Sales Forecast 2017-2027
5.6.2 French Generic Drugs Market: Generic Penetration by Volume, 2001-2016
5.6.3 French Generic Drugs Market: Generic Penetration by Value, 2001-2016
5.7 Italian Generic Drugs Market: Branded Generics Hindering Overall Growth
5.7.1 The Tightening of Italy’s Patent Legislations
5.7.2 The Italian Healthcare System – A Tale of Falling Budgets
5.7.3 Italian Generic Drugs Market: Sales Forecast: 2017-2027
5.7.4 Italian Generic Drugs market: Generic Penetration by Volume
5.7.5 Italian Generic Drugs Market: Generic Penetration by Value
5.8 Spanish Generic Drugs Market: Room for Growth
5.8.1 Cost-Containment Measures Helping to Boost Generic Drug Use
5.8.2 Spanish Generic Drugs Market: Sales Forecast 2017-2027
5.8.3 Spanish Generic Drugs Market: Generic Penetration by Volume, 2001-2016
5.8.4 Spanish Generic Drugs Market: Generic Penetration by Value, 2001-2016
6. Asia-Pacific Generic Drugs Market, 2017-2027
6.1 Generic Drugs in the Asia-Pacific Market: Market Overview
6.2 Chinese Generic Drugs Market: Domestic Companies Dominate the Market Landscape
6.2.1 The Major Drivers of Growth in the Chinese Generics Market
6.2.2 Chinese Generic Drugs Market: Sales Forecast 2017-2027
6.2.3 Compulsory Licensing of Generic Drugs
6.2.4 Expansion of Healthcare Coverage and Reimbursement
6.2.5 Chinese Generic Drugs Market: Generic Penetration by Volume, 2001–2016
6.2.6 Chinese Generic Drugs Market: Generic Penetration by Value, 2001-2016
6.2.7 The Impacts of Price Controls and the Anhui Model
6.3 Japanese Generic Drugs Market: High Barriers to Entry
6.3.1 Public Perception of Generics in Japan
6.3.2 Japanese Generic Drugs Market: Leading Companies
6.3.3 Japanese Generic Drugs Market: Sales Forecast 2017-2027
6.3.4 Japanese Generic Drugs Market: Generic Penetration by Volume, 2001–2016
6.3.5 Japanese Generic Drugs Market: Generic Penetration by Value, 2001-2016
6.3.6 Government Initiatives Driving Generic Penetration
6.3.7 Japanese Attitudes to Generic Drugs
6.4 Indian Generic Drugs Market: Regulatory Failures Hindering Sales Growth
6.4.1 Leading Companies in the Indian Generic Drugs Market
6.4.2 Indian Generic Drugs Market: Sales Forecast 2017-2027
6.4.3 The Reforms to India’s Drug Prices Control Order and Its Likely Effects on Generic Drugs Revenues
6.4.4 Expansion of the National Healthcare Coverage Increases the Need for Generics
6.4.5 Has Recent Manufacturing Quality Failures Dented India’s Generics Growth?
7. Emerging Generic Drugs Market, 2017-2027
7.1 Generic Drugs in the Emerging Market: Market Overview
7.1.1 Emerging Economies: Improving Logistics and Better Infrastructure Catalysing Generics Growth
7.2 Brazil Generic Drugs Market
7.2.1 Brazilian Generic Drugs Market: Sales Forecast 2017-2027
7.2.2 Generics to Facilitate Low-Income Earner’s Access to Medicines
7.2.3 Foreign Generic Drug Manufacturers Entering the Brazilian Market
7.3 Russian Generic Drugs Market: Improving IP Protection to Aid Market Growth
7.3.1 Historical Trends in Russia’s Pharmaceutical Production and Distribution
7.3.2 The Pharma2020 Strategy - Healthcare and Industry Reform
7.3.3 Self-Medication in Russia and the Integral Role of Pharmacies
7.3.4 Russian Generic Drugs Market: Sales Forecast 2017-2027
7.4 Mexican Generic Drugs Market: Boost by Investment from the Government
7.4.1 Government Programmes to Vitalise Generic Penetration in Mexico
7.4.2 Regulatory Changes and the Inception of COFEPRIS
7.4.3 Mexican Generic Drugs Market: Sales Forecast 2017-2027
7.5 South Korean Generic Drugs Market: Expected to Continue Its Trend of Growth
7.5.1 Pharmaceutical Price Controls and Measures Being Implemented in South Korea
7.5.1.1 KORUS FTA: The Free Trade Agreement between South Korea and the US
7.5.1.2 The Free Trade Agreement between Korea and the European Union
7.5.2 South Korean Generic Drugs Market: Sales Forecast 2017-2027
7.6 Turkish Generic Drugs Market: Price Cuts May Impact the First Half of the Forecast Period
7.6.1 Cost Cutting Measures and their Effects on Turkish Generics
7.6.2 Will Turkey Become a Production Base for High Technology Products?
7.6.3 Turkish Generic Drugs Market: Sales Forecast 2017-2027
7.6.4 Regulatory Guidelines for Generic Drugs in Turkey
7.6.5 How Effective has Turkey’s Health Transformation Programme Been?
8. Leading Companies in The Generic Drugs Market, 2017-2027
8.1 Generic Drugs: Continuous Expansion to Rival
8.1.1 The Leading Companies in the Global Generics Market
8.2 Teva
8.2.1 Teva: Historical Financial and Performance Analysis, 2011-2015
8.2.2 Teva Generic Drugs Sales Forecast 2017-2027
8.2.3 Teva and Allergan Spin-Off Generic Drug Deal
8.2.4 Allergan: Historical Financial and Performance Analysis, 2011-2015
8.2.5 Allergan: Developments in Generic Drug Segment Prior Mega-Deal
8.2.5.1 Exit from the Chinese Generics Market
8.2.5.2 Further Entry into the Japanese Generics Market
8.2.6 Teva: Generic Drugs Portfolio Analysis, 2017
8.2.6.1 High-Value Generics to Drive Teva’s Generics Growth?
8.2.6.2 The Shift Towards Innovation
8.2.6.3 Glatiramer Acetate Injection Leads Teva’s Moving Focus
8.2.6.4 The Threat of Generic Erosion to Teva’s Products
8.2.7 Teva: What Future Moves Could We Expect?
8.3 Novartis
8.3.1 Novartis: Historical Financial and Performance Analysis, 2011-2015
8.3.2 Novartis Generic Drugs Sales Forecast 2017-2027
8.3.3 Novartis Generic Drugs Portfolio Analysis, 2017
8.3.3.1 Emphasis on Difficult-to-Manufacture Products
8.3.4 What Does the Future Hold for Novartis’ Generic Drugs Business?
8.4 Mylan
8.4.1 Mylan: Historical Financial and Performance Analysis, 2011-2015
8.4.2 Mylan Generic Drugs Sales Forecast 2017-2027
8.4.3 Mylan: Recent Developments
8.4.3.1 Acquisition of Abbott’s Generic Business
8.4.3.2 Mylan’s Growth in Manufacturing Capacity
8.4.3.3 Mylan Acquires Rights to GSK’s Advair, Diskus and Seretide
8.4.3.4 The Race to Market Capoxone Generics
8.4.3.5 Strategic Acquisition of Agila Expands Mylan’s Injectables Business
8.4.4 Mylan’s Collaborative Efforts
8.4.4.1 Biosimilar Collaboration with India’s Biocon
8.4.4.2 Biosimialr Collaborations with Momenta
8.4.5 What Does the Future Hold for Mylan’s Generic Drugs Business?
8.5 Pfizer
8.5.1 Pfizer: Historical Financial and Performance Analysis, 2011-2015
8.5.2 Pfizer’s Restructuring Strategy
8.5.3 Pfizer’s Done Deal with Hospira
8.5.4 Pfizer Generic Drugs Sales Forecast 2017-2027
8.5.5 Hospira: A Brief Overview of Operations
8.5.6 Hospira: Historical Financial and Performance Analysis 2011-2015
8.5.7 Hospira: Recent Developments
8.5.7.1 Hospira’s Expansion through Strategic Acquisitions Hospira: Manufacturing Concerns and Remediation Efforts
8.5.8 Future Prospects for Pfizer’s Generic Business
8.5.8.1 The Pfizer-Allergan Deal Falls Through
8.5.8.2 Activities of Allergan (Actavis) Prior to Mega-Merger
8.5.8.3 Actavis’ Work on Biosimilars
8.6 Abbott
8.6.1 Abbott: Historical Financial and Performance Analysis, 2011-2015
8.6.2 Abbott Generic Drugs Sales Forecast 2017-2027
8.6.3 Abbott: Recent Developments
8.6.3.1 Abbott after the Spin-Off of AbbVie – The Established Products Business Segment
8.6.3.2 Acquisition of Solvay Pharmaceutcials and Piramal Healthcare Solutions
8.6.3.3 Acquisition of CFR Pharmaceuticals Opens New Markets
8.6.4 What Does the Future Hold for Abbott’s Generic Drugs Business?
8.7 Sun Pharma
8.7.1 Sun Pharma’s Business Areas
8.7.2 Sun Pharma: Historical Financial and Performance Analysis, 2011-2015
8.7.3 Sun Pharma Generic Drugs Sales Forecast 2017-2027
8.7.4 Sun Pharma-Ranbaxy Acquisition
8.8 Aspen
8.8.1 Aspen: Historical Financial and Performance Analysis, 2011-2015
8.8.2 Aspen Generic Sales Forecast 2017-2027
8.8.3 Aspen: Recent Developments
8.8.3.1 Aspen Acquires Merck MSD’s Dutch API Plant
8.8.3.2 Acquisition of GSK’s Anti-Thrombosis Brands
8.8.4 Future Outlook for Aspen’s Generic Business
8.9 Fresenius Kabi
8.9.1 Fresenius Kabi: Historical Financial and Performance Analysis, 2011-2015
8.9.2 Fresenius Kabi Generic Drugs Sales Forecast 2017-2027
8.9.3 InnoPharma Licensing Deal Bolsters Portfolio Grown Via Past Acquisitions
8.9.4 Fresenius Kabi’s Joint Venture with PT Soho Global Health
8.9.5 Future Prospects for Fresenius Kabi’s Generics Business
8.10 Sanofi
8.10.1 Sanofi: Historical Financial and Performance Analysis, 2011-2015
8.10.2 Sanofi Generic Sales Forecast 2017-2027
8.10.3 Sanofi’s Response to Lantus Competition
8.10.3.1 Emerging Market Acquisitions
8.10.4 Sanofi’s Strategies to Develop Generic Sales
9. Qualitative Analysis of the Generic Drugs Market, 2017-2027
9.1 Market Factors Influencing the Global Generic Drugs Market
9.2 SWOT Analysis of the Global Generic Drugs Market, 2017-2027
9.2.1 Strengths
9.2.1.1 Improving Clarity around Regulatory Processes
9.2.1.2 The Continuous Government Support for Generic Manufacturers – Precursors for Innovation
9.2.1.3 Higher Pace of Growth Compared with Innovative Pharma
9.2.1.4 Globalisation and Its Impact on Manufacturing Capabilities
9.2.2 Weaknesses
9.2.2.1 Safety and Quality Concerns in the Manufacturing Process
9.2.2.2 The Non-Uniformity of Excipients
9.2.2.3 The Uncertainty around Patent Extensions and Exclusivities
9.2.2.4 Sceptical Physicians and the Negative Consumer Perception of Generics
9.2.2.5 Inefficiencies in Certain Regulatory Approval Processes
9.2.3 Opportunities
9.2.3.1 Higher Value Biosimilars and Branded Generics
9.2.3.2 Patent Expiries Creating Opportunities
9.2.3.3 Changing Scio-Economic Conditions Impacting Generic Drugs Demand
9.2.3.4 Emerging Markets – Expected to Drive Generics Volume Growth over Time
9.2.4 Threats
9.2.4.1 Government Cost-Cutting Initiatives Impacting on Generic Drugs Prices
9.2.4.2 The Complexity Surrounding Patents and Patents Expiries
9.2.4.3 Pharmacies and Healthcare Payer Consolidations
9.2.4.4 Possible Impacts of a Declining Pool
9.3 Porter’s Five Force Analysis of the Global Generic Drugs Market, 2017-2027
9.3.1 Power of Buyers: Medium
9.3.2 Power of Suppliers: Low
9.3.3 Rivalry among Competitors: High
9.3.4 Threat of New Entrants: High
9.3.5 Threat of Substitutes: Low
10. Conclusions
10.1 Overview of Current Market Conditions and Market Forecast, 2017-2027
10.2 Generic Drugs as a Strategic Tool in Healthcare
10.3 Major Drivers of Growth for Generic Drugs, 2017-2027
10.4 The Regulatory Landscape for Generic Drugs
10.5 Leading Generic Drug Manufacturers
10.6 Future Outlook for the Leading Regions within the Global Generic Drugs Market, 2017-2027
10.7 Generic Penetration by Volume in Leading National Markets
10.8 What Does the Future Hold for the Global Generic Drugs Market?
11. Glossary
Appendix
Visiongain’s Bespoke Research Service
Some Associated Reports
Visiongain Report Sales Order Form
About Visiongain
Report Evaluation Form
List of Tables
Table 1.1 Global Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by National Markets, 2015-2027 (Redacted Data)
Table 2.1 Types of Drug Names, 2017
Table 2.2 Currency Exchange Rates, 2016
Table 3.1 The Global Generic Drugs Market Size: Revenue ($bn) and Market Share (%) by Leading National Markets, 2015 and 2016
Table 3.2 The Global Generic Drugs Market Size: Revenue ($bn) and Market Share (%) by Region, 2015 and 2016
Table 3.3 The Global Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 3.4 The Global Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Region, 2015-2027
Table 3.5 The Global Generic Drugs Market Forecast: Market Share (%) by Region, 2015, 2021, and 2027
Table 3.6 The Global Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by National Market, 2015-2027
Table 3.6 (cont’d) The Global Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by National Market, 2015-2027
Table 3.7 The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2015-2021, 2021-2027, 2015-2027
Table 3.8 The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2015, 2021, and 2027
Table 3.9 Global Generic Drugs Market Drivers and Restraints, 2015-2027
Table 4.1 US Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%) 2005-2016
Table 4.2 US Generic Drugs Market Drivers and Restraints, 2017-2027
Table 4.3 US Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 5.1 The EU5 Generic Drugs Market: Revenue ($bn) and Market Share (%) by Country, 2015 and 2016
Table 5.2 EU5 Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 5.3 The EU5 Generic Drugs Market: Market Share (%) by Country, 2015, 2021, 2027
Table 5.4 The German Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 5.5 German Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2001-2016
Table 5.6 German Generic Drugs Market: Generic Penetration by Proportion of Total Pharmaceutical Sales (%) and AGR (%), 2001-2016
Table 5.7 The UK Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 5.8 UK Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2001-2016
Table 5.9 UK Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2001-2016
Table 5.10 The French Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 5.11 French Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2001-2016
Table 5.12 French Generic Drugs Market: Generic Penetration by Proportion of Total Pharmaceutical Sales (%) and AGR (%), 2001-2016
Table 5.13 The Italian Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 5.14 Italian Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2001-2017
Table 5.15 Italian Generic Drugs Market: Generic Penetration by Proportion of Total Pharmaceutical Sales (%) and AGR (%), 2001-2016
Table 5.16 The Spanish Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and (CAGR%), 2015-2027
Table 5.17 Spanish Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2001-2016
Table 5.18 Spanish Generic Drugs Market: Generic Penetration of Total Pharmaceutical Sales (%) and AGR (%), 2001-2016
Table 6.1 The Chinese Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 6.2 Chinese Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2001-2016
Table 6.3 Chinese Generic Drugs Market: Generic Penetration by Proportion of Total Pharmaceutical Sale (%) and AGR (%), 2001-2016
Table 6.4 The Japanese Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 6.5 Japanese Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2001-2016
Table 6.6 Japanese Generic Drugs Market: Generic Penetration by Proportion of Total Pharmaceutical Sales (%) and AGR (%), 2001-2016
Table 6.7 The Indian Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 6.8 Leading Drug Types in Indian Pharmaceutical Market: Revenue ($bn) and Market Share (%), 2016, 2021 & 2027
Table 7.1 The Brazilian Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 7.2 The Russian Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 7.3 The Mexican Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 7.4 The South Korean Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 7.5 The Turkish Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 8.1 Top Generic Drugs Manufacturers: Total Revenue ($bn), Generic Drugs Revenue ($bn) and Generic Share of Revenue (%), 2015 and 2016
Table 8.2 Teva: Company Overview, 2015-2016
Table 8.3 Teva: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
Table 8.4 Teva Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 8.5 Allergan: Company Overview 2015-2016
Table 8.6 Allergan: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
Table 8.7 Novartis: Overview, 2015-2016
Table 8.8 Novartis: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
Table 8.9 Novartis Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 8.10 Mylan: Company Overview, 2015-2016
Table 8.11 Mylan: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
Table 8.12 Mylan: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 8.13 Pfizer: Company Overview, 2015-2016
Table 8.14 Pfizer: Historical ‘Established Products’ Drugs Sales ($bn) and AGR (%), 2011-2015
Table 8.15 Pfizer: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 8.16 Hospira: Company Overview, 2014-2015
Table 8.17 Hospira: Historical Specialty Injectables Sales ($bn) and AGR (%), 2011-2015
Table 8.18 Allergan: Company Overview, 2015-2016
Table 8.19 Abbott: Company Overview, 2015-2016
Table 8.20 Abbott: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
Table 8.21 Abbott: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 8.22 Sun Pharmaceuticals: Company Overview, 2015-2016
Table 8.23 Sun Pharma: Historical Generic Drugs Sales ($bn), 2011-2015
Table 8.24 Sun Pharma Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 8.25 Aspen: Company Overview, 2015-2016
Table 8.26 Aspen: Historical Revenue ($bn) and AGR (%), 2011-2015
Table 8.27 Aspen Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 8.28 Fresenius Kabi: Company Overview, 2015-2016
Table 8.29 Fresenius Kabi: Historical Generic Drugs Sales ($bn), 2011-2015
Table 8.30 Fresenius Kabi: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 8.31 Sanofi: Company Overview, 2015-2016
Table 8.32 Sanofi: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
Table 8.33 Sanofi Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 9.1 SWOT Analysis of the Generic Drugs Market, 2017-2027
Table 9.2 World 65+ Population Forecast: Size (m), AGR (%) and CAGR (%), 2015-2027
Table 10.1 Global Generic Drugs Market Forecast: Revenue ($bn) and CAGR (%), 2015, 2021 and 2027
Table 10.2 Top Generic Drug Manufacturers: Generic Drugs Revenue ($bn) and Market Share (%), 2016
Table 10.3 Global Generic Drugs Market Forecast: Revenue ($bn) by National Markets, 2015, 2021 and 2027
Table 10.4 US, EU5 and Japan Generic Drugs Market Forecast: Revenue ($bn), 2015-2027
Table 10.5 BRIC Generic Drugs Market Forecast: Revenue ($bn), 2015-2027
Table 10.6 Mexico, South Korea, and Turkey Generic Drugs Market Forecast: Revenue ($bn), 2015-2027
Table 10.7 Generic Drug Penetration by Volume in Leading National Markets (%), 2016
List of Figures
Figure 1.1 Global Generic Drugs Market Segmentation
Figure 2.1 EU Data Exclusivity for Generics: Possible Scenarios, 2016
Figure 3.1 The Global Generic Drugs Market Size: Revenue ($bn) by Leading National Markets, 2015
Figure 3.2 The Global Generic Drugs Market Size: Revenue ($bn) by Leading National Markets, 2016
Figure 3.3 The Global Generic Drugs Market Size: Revenue ($bn) by Region, 2015
Figure 3.4 The Global Generic Drugs Market Size: Revenue ($bn) by Region, 2016
Figure 3.5 Global Generic Drugs Market Forecast: ($bn) and AGR (%), 2015-2027
Figure 3.6 The Global Generic Drugs Market Forecast: Market Share (%) by Region, 2015
Figure 3.7 The Global Generic Drugs Market Forecast: Market Share (%) by Region, 2021
Figure 3.8 The Global Generic Drugs Market Forecast: Market Share (%) by Region, 2027
Figure 3.9 The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2015-2021
Figure 3.10 The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2021-2027
Figure 3.11 The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2015-2027
Figure 3.12 The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2015
Figure 3.13 The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2021
Figure 3.14 The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2027
Figure 4.1 US Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%) 2005-2016
Figure 4.2 US Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2015-2027
Figure 5.1 The EU5 Generic Drugs Market: Revenues ($bn) by Country, 2015
Figure 5.2 The EU5 Generic Drugs Market: Revenues ($bn) by Country, 2016
Figure 5.3 Germany, France, UK, Italy, and Spain Generic Drugs Market Forecast: Revenue ($bn), 2015-2027
Figure 5.4 The EU5 Generic Drugs Market: Market Share (%) by Country, 2015
Figure 5.5 The EU5 Generic Drugs Market: Market Share (%) by Country, 2021
Figure 5.6 The EU5 Generic Drugs Market: Market Share (%) by Country, 2027
Figure 5.7 The German Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2027
Figure 5.8 German Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2001-2016
Figure 5.9 German Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2001-2016
Figure 5.10 The UK Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2027
Figure 5.11 UK Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2001-2016
Figure 5.12 UK Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2001-2016
Figure 5.13 The French Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2027
Figure 5.14 French Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2001-2016
Figure 5.15 French Generic Drugs Market: Generic Penetration by Proportion of Total Pharmaceutical sales (%) and AGR (%), 2001-2016
Figure 5.16 The Italian Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2027
Figure 5.17 Italian Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2001-2016
Figure 5.18 Italian Generic Drugs Market: Generic Penetration by Proportion of Total Pharmaceutical Sales (%) and AGR (%), 2001-2016
Figure 5.19 The Spanish Generic Drugs Market Forecast: Revenue ($bn), AGR (%) , 2015-2027
Figure 5.20 Spanish Generic Drugs Market: Generic Penetration by Volume of Prescriptions (%) and AGR (%), 2001-2016
Figure 5.21 Spanish Generic Drugs Market: Generic Penetration by Proportion of Pharmaceutical Sales (%) and AGR (%), 2001-2016
Figure 6.1 China, Japan and India Generic Drugs Market Forecast: Revenue ($bn), 2015-2027
Figure 6.2 The Chinese Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2027
Figure 6.3 Chinese Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2001-2016
Figure 6.4 Chinese Generic Drugs Market: Generic Penetration by Proportion of Total Pharmaceutical Sale (%) and AGR (%), 2001-2016
Figure 6.5 The Japanese Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2015-2027
Figure 6.6 Japanese Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%) 2001-2016
Figure 6.7 Japanese Generic Drugs Market: Generic Penetration by Proportion of Total Pharmaceutical Sales (%) and AGR (%) 2001-2016
Figure 6.8 The Indian Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2015-2027
Figure 6.9 Leading Drug Types in Indian Pharmaceutical Market: Market Share (%), 2016
Figure 6.10 Leading Drug Types in Indian Pharmaceutical Market: Market Share (%), 2021
Figure 6.11 Leading Drug Types in Indian Pharmaceutical Market: Market Share (%), 2027
Figure 7.1 Brazil, Russia, Mexico, South Korea and Turkey Generic Drugs Market Forecast: Revenue ($bn), 2015-2027
Figure 7.2 The Brazilian Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2015-2027
Figure 7.3 The Russian Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2027
Figure 7.4 The Mexican Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2027
Figure 7.5 The South Korean Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2015-2027
Figure 7.6 The Turkish Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2027
Figure 8.1 Top Generic Drugs Manufacturers: Generic Drugs Revenue ($bn), 2015
Figure 8.2 Top Generic Drugs Manufacturers: Generic Drugs Revenue ($bn), 2016
Figure 8.3 Teva: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
Figure 8.4 Teva Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2015-2027
Figure 8.5 Allergan: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
Figure 8.6 Novartis: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
Figure 8.7 Novartis Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2015-2027
Figure 8.8 Mylan: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
Figure 8.9 Mylan: Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2015-2027
Figure 8.10 Pfizer: Historical ‘Established Products’ Drugs Sales ($bn) and AGR (%), 2011-2015
Figure 8.11 Pfizer Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2015-2027
Figure 8.12 Hospira: Historical Specialty Injectables Sales ($bn) and AGR (%), 2011-2015
Figure 8.13 Abbott: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
Figure 8.14 Abbott Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2015-2027
Figure 8.15 Sun Pharma: Historical Generic Drugs Sales (Rs.bn) and AGR (%), 2011-2015
Figure 8.16 Sun Pharma: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
Figure 8.17 Sun Pharma Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2015-2027
Figure 8.18 Aspen: Historical Revenue ($bn) and AGR (%), 2011-2015
Figure 8.19 Aspen: Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2015-2027
Figure 8.20 Fresenius Kabi: Historical Generic Drugs Sales (€bn) and AGR (%), 2011-2015
Figure 8.21 Fresenius Kabi: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
Figure 8.22 Fresenius Kabi Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2015-2027
Figure 8.23 Sanofi: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
Figure 8.24 Sanofi Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2015-2027
Figure 9.1 World 65+ Population Forecast: Size (m) and AGR (%), 2015-2027
Figure 9.2 Porter’s Five Force Analysis of the Global Generic Drugs Market, 2017
Figure 10.1 Global Generic Drugs Market Forecast: Revenue ($bn), 2015, 2021 and 2027
Figure 10.2 US, EU5 and Japan Generic Drugs Market Forecast: Revenue ($bn), 2015-2027
Figure 10.3 BRIC Generic Drugs Market Forecast: ($bn), 2015-2027
Figure 10.4 Mexico, South Korea, and Turkey Generic Drugs Market Forecast: Revenue ($bn), 2015-2027
Figure 10.5 Generic Drug Penetration by Volume in Leading National Markets (%), 2016
Abbott
AbbVie
Actavis
Alcon (Novartis)
Allergan (Actavis)
Amgen
Anda Inc
APP Pharmaceuticals
Arrow Group (Actavis)
Ascent Pharmahealth (Actavis)
ASKA Pharmaceuticals
Aspen
AstraZeneca
Bergamo (Amgen)
Bioniche Pharma (Mylan)
BMP Sunstone (Sanofi)
CFR Pharmaceuticals (Abbott)
Cipla
Dabur Pharma (Fresenius Kabi)
Daiichi Sankyo
Dalim BioTech
Dr Reddy’s Laboratory
Ebewe Pharma (Novartis)
Eden Biopharm Group
Egis
Elder Pharmaceuticals (Torrent Pharmaceuticals)
Eli Lilly
Elyson Pharmaceuticals
EMS Sigma Pharma
Eurofarma Laboratories
Farmacias Similares
Fenwal (Fresenius Kabi)
Forest Laboratories (Actavis)
Foshan Chanbende Development
Fougera Pharmaceuticals (Novartis)
Fresenius Kabi
Fresenius SE & Co
Fuji Pharma
Gedeon Richter
Genfar S.A (Sanofi)
Genzyme (Sanofi)
Gilead Sciences
GlaxoSmithKline (GSK)
Greenstone (Pfizer)
Grupo Sanborns
Grupo Uriach
Hospira (Pfizer)
IDEV Technologies (Abbott)
Ilsung Pharmaceuticals
InnoPharma Inc
Itero Biopharmaceuticals
Janssen
Javelin Pharmaceuticals (Hospira)
Kmart
KMS Pharmaceutical
Kowa Pharmaceuticals
Krka
Labesfal Genéricos (Fresenius Kabi)
Laboratorio Sanderson (Fresenius Kabi)
Laboratorios Best
Laboratorios Kendrick (Sanofi)
Lek (Novartis)
Lupin
Mayne Pharma (Hospira)
Medley (Sanofi)
Merck KGaA
MN Pharma (Amgen)
Momenta Pharmaceuticals
Mylan
Natco Pharma
Nexus Pharmaceuticals
Nichi-Iko
Nippon Chemiphar
Novartis (Sandoz)
Novo Nordisk
OptiMedica (Abbott)
Orchid Chemicals & Pharmaceuticals
Oriel Therapeutics (Novartis)
Parenteral Drugs India Ltd
Perrigo
Pfizer
Piramal (Abbott Laboratories)
Pliva (Teva)
PT Soho Global Health
Ranbaxy (Sun Pharmaceuticals)
Rimsa
Roche
Sabex (Novartis)
Sanofi
Sawai Pharmaceuticals
Schein Pharmaceutical (Actavis)
Shelys (Aspen)
Sigma Pharmaceuticals (Aspen)
Solvay Pharmaceuticals (Abbott)
Specifar Pharmaceuticals (Actavis)
STADA Arzneimittel
Sun Pharma
Synthon
Takeda
Taiyo Pharmaceuticals
Teuto Brasileiro (Pfizer)
Teva
The Laboratory of Analytical Services International Ltd
Towa
UDL Laboratories
Uteron Pharma (Actavis)
Valeant Pharmaceuticals
Wal-Mart
Warner Chilcott (Actavis)
Wockhardt
Wyeth (Pfizer)
Zentiva (Sanofi)
Zhejiang Chiral Medicine Chemicals Co. Ltd
Zhejiang Hisun Pharmaceutical
Zydus Cadila
List of Organizations Mentioned in the Report
Assogenerici [Italy]
Blue Cross Blue Shield Association (BCBSA) [US]
British Generic Manufacturers Association (BGMA)
Caisse Nationale de l’Assurance Maladie (CNAM) [France]
Center for Drug Evaluation and Research (CDER) [US]
Centers for Medicare and Medicaid Services [US]
China Food and Drug Administration (CFDA)
COFEPRIS [Mexico]
Competion and Markets Authority (CMA) [UK]
Congressional Budget Office (CBO) [US]
European Commission
European Generics Medicines Association (EGA)
European Medicines Agency (EMA)
European Patent Office (EPO)
Federal Trade Commission (FTC) [US]
Federal Commission for the Protection against Sanitary Risk (COFEPRIS)
Food and Drugs Administration (FDA) [US]
Gesundheitsberichterstattung des Bundes (Federal Health Monitoring System, Germany)
General Adminsistratioon of Quality Supervision, Inspection and Quarantine (AQSIQ) [China]
General Directorate of Pharmaceuticals and Pharmacy (GDPP) [Turkey]
Medicine and Healthcare products Regulatory Agency (MHRA)
Ministry of Health, Labour and Welfare (MHLW) [Japan]
Ministry of Human Resources and Social Security (MOHRSS)
National Development and Reform Commission (NDRC)
National Health Service (NHS)
National Pharmaceutical Pricing Authority [India]
Pan American Health Organization (PAHO)
Pharmaceutical and Medical Devices Agency (PMDA) [Japan]
Queen Mary University of London
Servicio Sanitario Nazionale (SSN) [Italy]
United Nations’ Department of Economic and Social Affairs
US Generic Pharmaceutical Association (GPhA)
Veropharm (Abbott)
World Health Organization (WHO)
World Trade Organisation (WTO)
Download sample pages
Complete the form below to download your free sample pages for Generic Drugs Market Forecast 2017-2027Download sample pages
Complete the form below to download your free sample pages for Generic Drugs Market Forecast 2017-2027Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: jamie.roberts@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Jamie Roberts stating your chosen report title to jamie.roberts@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email jamie.roberts@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Drug Delivery Technologies Market Report 2024-2034
The global Drug Delivery Technologies market is estimated at US$1,729.6 billion in 2024 and is projected to grow at a CAGR of 5.5% during the forecast period 2024-2034.
23 April 2024
Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034
The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.
18 April 2024
Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034
The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.
17 April 2024
Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034
The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.
12 April 2024
